Laboratory Co. of America Holdings (NYSE:LH - Get Free Report) COO Mark S. Schroeder sold 5,339 shares of Laboratory Co. of America stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $249.23, for a total value of $1,330,638.97. Following the transaction, the chief operating officer now directly owns 4,960 shares in the company, valued at approximately $1,236,180.80. This trade represents a 51.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Laboratory Co. of America Stock Performance
Shares of Laboratory Co. of America stock traded down $1.07 during trading on Friday, reaching $253.00. The company's stock had a trading volume of 801,584 shares, compared to its average volume of 607,434. The business's fifty day moving average price is $243.23 and its 200-day moving average price is $233.48. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $258.59. The firm has a market cap of $21.18 billion, a price-to-earnings ratio of 28.68, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44.
Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, topping analysts' consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, equities research analysts predict that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.
Laboratory Co. of America Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be given a $0.72 dividend. The ex-dividend date is Thursday, February 27th. This represents a $2.88 annualized dividend and a yield of 1.14%. Laboratory Co. of America's dividend payout ratio is 32.65%.
Analyst Ratings Changes
LH has been the topic of a number of recent research reports. Barclays lowered their target price on Laboratory Co. of America from $271.00 to $260.00 and set an "equal weight" rating on the stock in a research note on Friday, February 7th. Evercore ISI upgraded Laboratory Co. of America from an "in-line" rating to an "outperform" rating and increased their price objective for the stock from $260.00 to $265.00 in a report on Tuesday, January 7th. Bank of America lifted their target price on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a "buy" rating in a research note on Friday, December 13th. Morgan Stanley raised their price target on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company an "overweight" rating in a report on Tuesday, December 17th. Finally, Piper Sandler upped their price objective on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $268.38.
View Our Latest Research Report on LH
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in LH. Graney & King LLC acquired a new stake in Laboratory Co. of America during the fourth quarter worth about $26,000. SouthState Corp bought a new stake in shares of Laboratory Co. of America in the 3rd quarter worth approximately $28,000. Fortitude Family Office LLC grew its holdings in shares of Laboratory Co. of America by 312.5% during the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company's stock worth $30,000 after purchasing an additional 100 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in shares of Laboratory Co. of America by 309.8% in the fourth quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company's stock valued at $39,000 after purchasing an additional 127 shares in the last quarter. Finally, Human Investing LLC bought a new position in Laboratory Co. of America in the fourth quarter worth $39,000. Institutional investors own 95.94% of the company's stock.
About Laboratory Co. of America
(
Get Free Report)
Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Read More
Before you consider Laboratory Co. of America, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Laboratory Co. of America wasn't on the list.
While Laboratory Co. of America currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
